Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JD002 (Xuzhou Medical University)
- Development stage
- Phase 1
- Lead developer
- Xuzhou Medical University
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
JD002 is an investigational allogeneic natural killer (NK) cell therapy developed by Xuzhou Medical University for the treatment of relapsed or refractory acute myeloid leukemia (AML). It is specifically being evaluated in patients who have experienced disease recurrence following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The therapy involves the infusion of donor-derived NK cells, which are intended to induce a graft-versus-leukemia (GVL) effect by identifying and destroying residual leukemic blasts through innate immune mechanisms. In clinical trials, JD002 is administered in conjunction with azacitidine, a hypomethylating agent, to potentially sensitize leukemia cells to NK-mediated lysis and improve clinical outcomes.
- Other names
- allogenic NK cellsallogeneic natural killer cells
Beyond the preview
Go deeper on JD002 (Xuzhou Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JD002 (Xuzhou Medical University).